Roche Holding AG Share Price Berne S.E.

Equities

ROG

CH0012032048

Pharmaceuticals

Delayed Berne S.E. 09:30:02 17/04/2024 pm IST 5-day change 1st Jan Change
220.7 CHF -0.05% Intraday chart for Roche Holding AG -1.35% -9.54%

Financials

Sales 2024 * 6.05TCr 6.76TCr 5,64900Cr Sales 2025 * 6.38TCr 7.14TCr 5,96300Cr Capitalization 21TCr 23TCr 19,53300Cr
Net income 2024 * 1.34TCr 1.5TCr 1,25500Cr Net income 2025 * 1.49TCr 1.66TCr 1,38700Cr EV / Sales 2024 * 3.69 x
Net Debt 2024 * 1.43TCr 1.6TCr 1,33400Cr Net Debt 2025 * 919.36Cr 1.03TCr 86TCr EV / Sales 2025 * 3.42 x
P/E ratio 2024 *
15.1 x
P/E ratio 2025 *
13.8 x
Employees -
Yield 2024 *
3.78%
Yield 2025 *
3.88%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

Managers TitleAgeSince
Chief Executive Officer 49 01/03/01
Chairman 57 01/08/01
Director of Finance/CFO 57 01/11/01
Members of the board TitleAgeSince
Director/Board Member 72 03/15/03
Director/Board Member 59 -
Director/Board Member 66 01/96/01
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.7 CHF
Average target price
274 CHF
Spread / Average Target
+5.91%
Consensus
1st Jan change Capi.
+61.53% 86TCr
+38.95% 63TCr
-3.66% 36TCr
+15.06% 32TCr
+9.18% 30TCr
+16.53% 23TCr
+15.67% 18TCr
+2.47% 16TCr
+2.41% 13TCr
Other Pharmaceuticals